Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Bone Marrow Transplantation, Published online: 02 December 2023; doi:10.1038/s41409-023-02150-wComparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Source: Bone Marrow Transplantation - December 2, 2023 Category: Hematology Authors: Jes ús Duque-Afonso J ürgen Finke Maud Ngoya Jacques-Emmanuel Galimard Charles Craddock Kavita Raj Adrian Bloor Emma Nicholson Matthias Eder Orchard Kim Thomas Valerius John A. Snowden Eleni Tholouli Charles Crawley Matthew Collin Keith M. O. Wilson Ala Source Type: research